CSL Behring
A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults
- Conditions
- Healthy Volunteers
- Interventions
- Biological: CSL312
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 38
- Registration Number
- NCT04580654
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
- Conditions
- Healthy
- Interventions
- Biological: CSL324Drug: Placebo
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 32
- Registration Number
- NCT04570267
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, Australia
CSL324 in COVID-19
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Drug: PlaceboBiological: CSL324
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- CSL Behring
- Registration Number
- NCT04519424
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects
- Conditions
- Immune Complex-mediated Autoimmune Diseases
- Interventions
- Biological: CSL730Drug: Placebo
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 52
- Registration Number
- NCT04446000
- Locations
- 🇬🇧
PAREXEL Early Phase Clinical Unit (London), Northwick Park Hospital, Harrow, United Kingdom
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
- Conditions
- Diabetic Kidney Disease (DKD)
- Interventions
- Biological: CSL346Drug: Placebo
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 114
- Registration Number
- NCT04419467
- Locations
- 🇺🇸
California Kidney Specialists (CKS) - Citrus Office, Covina, California, United States
🇺🇸Valley Research - Fresno, Fresno, California, United States
🇺🇸Torrance Clinical Research (TCR) - Lomita, Lomita, California, United States
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Biological: Garadacimab, Factor XIIa Antagonist Monoclonal AntibodyDrug: Placebo
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 124
- Registration Number
- NCT04409509
- Locations
- 🇺🇸
Nova Clinical Research, LLC, Bradenton, Florida, United States
🇺🇸Theia Clinical Research, LLC, Saint Petersburg, Florida, United States
🇺🇸MercyOne North Iowa Medical Center, Mason City, Iowa, United States
Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- Interventions
- Biological: CSL889
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 28
- Registration Number
- NCT04285827
- Locations
- 🇺🇸
University of Illinois Hospital and Health Science Systems, Chicago, Illinois, United States
🇺🇸The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- CSL Behring
- Registration Number
- NCT04281524
Respreeza® Self-administration and Learning Program (AmAREtTI Study)
- Conditions
- Alpha-1 Antitrypsin Deficiency
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 15
- Registration Number
- NCT04262284
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CHU Bordeaux - Hôpital Haut-Lévèque, Bordeaux, France
🇫🇷CHU Grenoble-Alpes, Grenoble, France
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)
- Conditions
- Graft Versus Host Disease (GVHD)
- Interventions
- Biological: Alpha-1 antitrypsin (AAT)Drug: Placebo
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 136
- Registration Number
- NCT04167514
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States